P2X7 receptor agonists pre-and postcondition the heart against ischemia-reperfusion injury by opening pannexin-1/P2X7 channels

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 3, 2011, Pages

  Vessey, Donald A ^a,b   Li, Luyi ^a   Kelley, Michael ^a  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Benzoyl benzoyl adenosine 5' triphosphate; Cardioprotection; G protein coupled receptors; Hemichannels; P2x7; Phospho Akt; Receptor; Sphingosine 1 phosphate

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZOYL BENZOYL ADENOSINE TRIPHOSPHATE; BRILLIANT BLUE; CARBENOXOLONE; MEFLOQUINE; PURINERGIC P2X7 RECEPTOR; SPHINGOSINE 1 PHOSPHATE; SURAMIN; UNCLASSIFIED DRUG; 3' O (4 BENZOYL)BENZOYLADENOSINE 5' TRIPHOSPHATE; 3'-O-(4-BENZOYL)BENZOYLADENOSINE 5'-TRIPHOSPHATE; CARDIOTONIC AGENT; DRUG DERIVATIVE; GAP JUNCTION PROTEIN; LYSOPHOSPHOLIPID; NERVE PROTEIN; PANNEXIN 1, RAT; PURINERGIC P2X RECEPTOR AGONIST; PURINERGIC P2X RECEPTOR ANTAGONIST; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1-PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; EX VIVO STUDY; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; ANALYSIS OF VARIANCE; ANIMAL; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECT; DRUG POTENTIATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE PRESSURE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PERFUSION; SPRAGUE DAWLEY RAT; TIME;

ADENOSINE TRIPHOSPHATE; ANALYSIS OF VARIANCE; ANIMALS; CARDIOTONIC AGENTS; CONNEXINS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; LYSOPHOSPHOLIPIDS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NERVE TISSUE PROTEINS; PERFUSION; PURINERGIC P2X RECEPTOR AGONISTS; PURINERGIC P2X RECEPTOR ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LYSOSPHINGOLIPID; RECEPTORS, PURINERGIC P2X7; SPHINGOSINE; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 80052339115     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00305.2011     Document Type: Article

References (39)

1. Bruzzone R, Barbe MT, Jakob NJ, Monyer H. Pharmacological properties of homomeric and heteromeric pannexin hemichannels expressed in Xenopus oocytes. J Neurochem 92: 1033-1043, 2005.
2. Buja LM, Entman ML. Modes of myocardial cell injury and cell death in ischemic heart disease. Circulation 98: 1355-1357, 1998.
3. Cohen MV, Downey JM. Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 103: 203-215, 2007.
4. Davis MD, Clemens JJ, Macdonald TL, Lynch KR. Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem 280: 9833-9841, 2005.
5. Evans WH, Leybaert L. Mimetic peptides as blockers of connexin channel-facilitated intercellular communication. Cell Commun Adhes 14: 265-273, 2007.
6. Gever JR, Cockayne DA, Dillon MP, Burnstock G, Ford AP. Pharmacology of P2X channels. Pflügers Arch 452: 513-537, 2006.
7. Gill C, Mestril R, Samali A. Losing heart: the role of apoptosis in heart disease-a novel therapeutic target? FASEB J 16: 135-146, 2002.
8. 2+ homeostasis. J Mol Cell Cardiol 47: 622-633, 2009.
9. Hansen PR. Myocardial reperfusion injury: experimental evidence and clinical relevance. Eur Heart J 16: 734-740, 1995.
10. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15: 69-75, 2004.
11. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288: H971-H976, 2005.
12. 7 receptor-pannexin1 complex: pharmacology and signaling. Am J Physiol Cell Physiol 295: C752-C760, 2008.
13. Jennings RB, Reimer KA. The cell biology of acute myocardial ischemia. Annu Rev Med 42: 225-246, 1991.
14. 7 receptors. Mol Pharmacol 58: 82-88, 2000.
15. 7 receptor death complex. FEBS Lett 581: 483-488, 2007.
16. Ma W, Hui H, Pelegrin P, Surprenant A. Pharmacological characterization of pannexin-1 currents expressed in mammalian cells. J Pharmacol Exp Ther 328: 409-418, 2009.
17. Matsui T, Rosenzweig A. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 38: 63-71, 2005.
18. Maxwell SR, Lip GY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol 58: 95-117, 1997.
19. Millart H, Alouane L, Oszust F, Chevallier S, Robinet A. Involvement of P2Y receptors in pyridoxal-5'-phosphate-induced cardiac preconditioning. Fundam Clin Pharmacol 23: 279-292, 2009.
20. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88: 581-609, 2008.
21. Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 66: 913-931, 1990.
22. 7 antagonists. J Med Chem 49: 3659-3666, 2006.
23. Oudit GY, Penninger JM. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 82: 250-260, 2009.
24. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R. Postconditioning and protection reperfusion injury: where do we stand? Cardiovasc Res 87: 406-423, 2010.
25. Peart JN, Headrick JP. Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther 114: 208-221, 2007.
26. Qiu F, Dahl G. A permeant regulating its permeation pore: inhibition of pannexin 1 channels by ATP. Am J Physiol Cell Physiol 296: C250-C255, 2009.
27. Scemes E, Suadicani SO, Dahl G, Spray DC. Connexin and pannexin mediated cell-cell communication. Neuron Glia Biol 3: 199-208, 2007.
28. Schultz JE, Gross GJ. Opiods and cardioprotection. Pharmacol Ther 89: 123-137, 2001.
29. Sumpio BE, Chaudry IH, Baue AE. Accelerated functional recovery of isolated rat kidney with ATP-MgCl2 following warm ischemia. Am J Physiol Regul Integr Comp Physiol 247: R1047-R1053, 1984.
30. Surprenant A, North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol 71: 333-359, 2009.
31. Vassort G. Adensine 5' triphosphate: a purinergic agonist in the mycardium. Physiol Rev 81: 767-806, 2001.
32. Vessey D, Kelley M, Li L, Huang Y, Zhou HZ, Zhu BQ, Karliner JS. Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit 12: BR318-BR324, 2006.
33. Vessey DA, Li L, Kelley M, Karliner JS. Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. Biochem Biophys Res Commun 375: 425-429, 2008.
34. Vessey DA, Li L, Kelley M, Karliner JS. Sphingosine can pre-and post-condition heart and utilizes a different mechanism from sphingosine 1-phosphate. J Biochem Mol Toxicol 22: 113-118, 2008.
35. Vessey DA, Li L, Honbo N, Karliner JS. Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre-and postconditioning. Am J Physiol Heart Circ Physiol 297: H1429-H1435, 2009.
36. 7 purinergic receptor channels mediate the release of cardioprotectants induced by ischemic pre-and postconditioning. J Cardiovasc Pharmacol Ther 15: 190-195, 2010.
37. 7 channels not only during preconditioning but again after index ischemia at full reperfsuion. Mol Cell Biochem 351: 77-84, 2011.
38. Zhao ZQ, Vinten-Johansen J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc Res 55: 438-455, 2002.
39. Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res 70: 200-211, 2006.